Dr. Reddy's Laboratories Ltd: Inventory Management Under Resource Constraints Custom Case Solution & Analysis

1. Evidence Brief: Case Extraction

Prepared by: Business Case Data Researcher

Financial Metrics

• Inventory Value: Dr. Reddys Laboratories (DRL) maintained inventory levels significantly higher than the industry average, with Days Inventory Outstanding (DIO) exceeding 90 days in certain segments.
• Holding Costs: Estimated annual inventory carrying cost is 18 to 22 percent of the total inventory value.
• Capital Allocation: Approximately 25 percent of current assets are tied up in inventory, impacting liquidity for R and D investments.
• Revenue Impact: Service levels for the Global Generics segment are targeted at 95 percent, but actual performance fluctuates between 88 and 92 percent.

Operational Facts

• SKU Complexity: The portfolio includes over 500 Stock Keeping Units (SKUs) across multiple therapeutic areas including oncology, cardiovascular, and diabetes.
• Production Constraints: Formulations Technical Operations (FTO) units operate with fixed batch sizes dictated by regulatory filings, preventing small-lot production.
• Lead Times: Cumulative lead times for active pharmaceutical ingredients (API) and formulations range from 60 to 120 days.
• Warehouse Capacity: Regional distribution centers are at 92 percent utilization, leaving minimal room for safety stock fluctuations.
• Demand Volatility: Monthly demand coefficient of variation (CV) for C-category items exceeds 0.8, indicating high unpredictability.

Stakeholder Positions

• Supply Chain Manager (Protagonist): Focuses on reducing DIO to free up working capital without compromising the 95 percent fill rate.
• Production Heads: Prioritize high capacity utilization and long production runs to minimize unit costs, resisting frequent changeovers.
• Sales and Marketing Teams: Demand 100 percent availability for A-category products and resist any inventory rationalization that might lead to stockouts.
• Quality Assurance: Maintains strict hold periods for testing, which adds a non-negotiable 10 to 14 days to the lead time.

Information Gaps

• Stockout Costs: The case does not provide the specific financial penalty or lost lifetime value of a customer for a missed order.
• Supplier Reliability: Data on the variance of API delivery times from external vendors is missing.
• Per-SKU Margin: Detailed contribution margins per SKU are not provided, making it difficult to prioritize based on profitability rather than volume.

2. Strategic Analysis

Prepared by: Market Strategy Consultant

Core Strategic Question

• How can DRL optimize its inventory-service level tradeoff to reduce working capital trapped in Global Generics while operating under rigid production batch sizes and limited warehouse capacity?

Structural Analysis

ABC-XYZ Matrix Findings:

• A-X Items (High Value, Low Volatility): These represent 70 percent of revenue but only 15 percent of SKUs. Current inventory levels are excessive due to over-buffering.
• C-Z Items (Low Value, High Volatility): These consume 40 percent of warehouse space while contributing less than 5 percent of margin. They are the primary cause of operational friction.
• Production Rigidity: The conflict between Economic Order Quantity (EOQ) and regulatory-mandated batch sizes creates a structural floor for inventory that cannot be lowered through traditional planning alone.

Strategic Options

Preliminary Recommendation

Implement the Segmented Inventory Policy immediately. DRL currently treats all SKUs with a similar service level target, which is inefficient. By rationalizing the tail (C-Z items) and focusing safety stock on high-margin A-X items, the company can reduce total inventory by 15 percent within two quarters without impacting core market presence.

3. Implementation Roadmap

Prepared by: Operations and Implementation Planner

Critical Path

• Month 1: Data Validation and Segmentation. Re-classify all 500 plus SKUs based on the last 24 months of actual demand volatility rather than forecasts.
• Month 2: Policy Redesign. Establish new safety stock targets. A-items move to a continuous review system; C-items move to a periodic review with lower frequency.
• Month 3: Production Alignment. Sync the Master Production Schedule (MPS) with the new inventory targets. Negotiate minimum run sizes for C-items with FTO units.
• Month 4: Pilot Launch. Apply the new policy to the top two therapeutic areas (Oncology and Cardiovascular).

Key Constraints

• Regulatory Rigidity: Changes to batch sizes or packaging locations require long lead times for health authority approvals.
• FTO Incentives: Current plant performance is measured by volume and recovery, which incentivizes overproduction. This must be shifted to service-level and DIO metrics.

Risk-Adjusted Implementation Strategy

To mitigate the risk of stockouts during the transition, a 10 percent safety buffer will be maintained for all A-category items for the first 90 days. The reduction in C-item inventory will be phased, starting with SKUs that have a shelf life of less than 6 months to prevent obsolescence write-offs.

4. Executive Review and BLUF

Prepared by: Senior Partner and Executive Reviewer

BLUF (Bottom Line Up Front)

DRL must abandon its uniform service level strategy and implement a segmented inventory model. The current DIO of 90 days is unsustainable and stems from an attempt to provide high availability for low-margin, high-volatility SKUs. By reducing service targets for the bottom 20 percent of products and optimizing buffers for the top 20 percent, DRL can release 45 million dollars in working capital. Execution depends on decoupling plant performance metrics from gross volume and realigning them with inventory velocity. Approval is recommended for the segmented pilot in the Global Generics unit.

Dangerous Assumption

The analysis assumes that demand volatility is an exogenous variable. In reality, DRL internal promotion cycles and end-of-quarter sales pushes often create the very volatility the supply chain struggles to manage. If the sales team continues these practices, inventory reductions will lead to immediate and artificial stockouts.

Unaddressed Risks

• API Supply Concentration: 60 percent of APIs are sourced from single-source vendors in specific geographies. Any inventory reduction at the formulation level increases vulnerability to upstream supply shocks. (Probability: Medium; Consequence: High)
• Regulatory Lead Times: The plan assumes production flexibility that may be legally prohibited by current filings. Failure to secure rapid approvals for batch size variations will stall the implementation. (Probability: High; Consequence: Medium)

Unconsidered Alternative

The team has not evaluated the total divestment or outsourcing of the C-Z SKU tail. If these products contribute negligible margin and consume disproportionate warehouse and management bandwidth, DRL should consider licensing these brands to smaller, more agile players rather than trying to optimize their internal management.

Verdict: APPROVED FOR LEADERSHIP REVIEW